Leaders in Pharmaceutical Business Intelligence (LPBI) Group

11:00AM – 10/1/2014: Scientific Collaborations  @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Reporter: Aviva Lev-Ari, PhD, RN

Real Time Media Conference Coverage  –  Business and Scientific Channels by:  https://pharmaceuticalintelligence.com

11:00AM – 10/1/2014: Scientific Collaborations

Introductory Speech by: 

• Ora Dar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, Israel – $70M gov. Budget

– IT is shared and used in collaboration

– Eight companies – 2 stem cells, Virtual Biopsy, Endoscopy

– 25% is from Academia rest from Industry

– Brain stimulation and Monitoring Technologies

– Synergies: with Roche; Pontifax

– collaboration announced 2009: new companies: BioVent, Quiet Therapeutics, cCAM

– Biotechnology Incubator – Government sponsored

— Advanced applied Research: Leveraging cultures of Innovations and Entrepreneurship

– Fund announced 4/2011 OrbiMed – $222M 4.5x Leverage Gov. commitment by OrbiMed

– PPPP – Public, Private, Philanthropy

Adaption to Change is critical not the smartest will survive

• Chaired by: 

Beth Jacobs, Managing Partner, Excellentia Global Partners

– complicated approaches of Scientific Collaborations

– Building Trust is it difficult?

– Tech transfer is having a bad rap

– Pharma tried avenues for efficiencies, Scientists in BIOTECH many are from Pharma, now their inventions go back to Pharma

Panelists: 

• Ora Dar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, Israel – $70M gov. Budget

– all gov. funding must by in conjunction with Private investment and commercialization ideas

– small companies needs IP to raise funding. University owns and license it to investors collaborations is in place

– Weitzman institute: antibodies platform, $17Billion sales

• Chris Maggos, Consultant, Business Development, Alpine Institute for Drug Discovery – Not for profit

– Platform development in Academia is allowing the University to maintain equity on Projects, Oversight from Pharma is important for the know how of the industrial process

– Trust will appear quickly after relationships are established

– Tech Transfer has a role to serve the Public, Europe Universities different than US Universities

• Edwin Constable, Head of Research, Professor of Chemistry at the University of Basel and Project leader and Member of the Management Board within the SNI, University of Basel

– Universities have different  responsibilities, public who fund Universities,juggle basic research and considering Pipeline of molecules, as a University the public good is different than a compound in a big Pharma, IP of university need be protected, identify drugs, collaborate with Hospitals for Clinical Trials

– IP need belong to the University but maintaining the IP and Protecting it may not be sensible.

– Primary PI has an idealist view of the World

– Universities need a new culture of entrepreneurship, failure in Academia is dreadful, not in Industry, risk taking need augmentations in Universities

– PPPP – three partners: Philanthropy – Gov. Axis is interesting

– disappointment – the role benefit for the Patient, drug distribution need be in place

– Translational model is the only proven others are correct and incorrect at the same time

– Monetizing IP:

– Translational Industry is in transition, where is it going?

• Florian Schoedel, MD, PhD, Owner, PhilImmune, LLC ex-Merck

– collaborations: Gov. and Biotech – start up can reach maturity. de-bridging goals, product concept in Biotech, if Gov. funding ends, no continuation of the idea pipeline

– translation of research, big Foundations, i.e., Gates Foundation, found the right way to fund research and commercialize drugs as vaccine and deploy at needy markets in underdeveloped countries

– PI needs often a change of mind, steps they do not know, Chem Engineering vs Chemistry major, i.e,

– Research dept inside Pharma changed very much, cheaper innovations from Academia and from Biotech – efficiencies are needed

• Maina Bhaman, Director, Healthcare Ventures, Imperial Innovations – Publicly listed

– Commercialization process and collaboration requires alignment, upfront time investment

– Transfer of IP, business that develop the molecule, then too much emphasis is placed on early IP

– Agrees, trust building is not easy

–

• Prem Das, Chief Research Business Development Officer and heads DFCI’s Office of Research and Technology Ventures (ORTV), Dana-Farber Cancer Institute (DFCI)

– Bio marker driven, cost consideration

– Diagnostics in Cancer – DGCI – is in competition with Foundations in the DIagnostics

– Infrastructure to develop the chemistry platform

– Gov funded research IP is owned by the Institution not by the Gov.

– Early stage IP: non-exclusive licensing

– Trust between the investigator and the commercializing entity, change attitude of PI needed, to make it work, the Scientists who is on a Journey

– gap exists in Academic mind vs industry

– R&D centers run by Scientists, Office of Innovation go to Scientists for solutions

QUESTION fro the audience

– Failure in Drug Development, why?

#startup#science#Collaboration #biotech #innovation #pharmanews

@SachsAssociates@pharma_BI@BloombergTV @BloombergNews @BiotechNews